We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.
- Authors
Kim, M. K.; Rhee, E.‐J.; Han, K. A.; Woo, A. C.; Lee, M.‐K.; Ku, B. J.; Chung, C. H.; Kim, K.‐A.; Lee, H. W.; Park, I. B.; Park, J. Y.; Chul Jang, H. C.; Park, K. S.; Jang, W. I.; Cha, B. Y.
- Abstract
The aim of the present study was to assess the efficacy and safety of teneligliptin in combination with metformin in Korean patients with type 2 diabetes mellitus who were inadequately controlled with metformin monotherapy. Patients [glycated haemoglobin ( HbA1c) 7.0-10.0%, on stable metformin ≥1000 mg/day] were randomized 2 : 1 to receive 20 mg teneligliptin plus metformin ( n = 136) or placebo plus metformin ( n = 68). The primary endpoint was the change in HbA1c levels from baseline to week 16. The mean baseline HbA1c was 7.9% in the teneligliptin group and 7.8% in the placebo group. The differences between the teneligliptin and placebo groups regarding changes in HbA1c and fasting plasma glucose levels were −0.78 % and −1.24 mmol/l (22.42 mg/dl), respectively, at week 16. The incidence of adverse events was similar between the groups. The addition of teneligliptin once daily to metformin was effective and generally well tolerated in Korean patients with type 2 diabetes.
- Subjects
KOREANS; PEOPLE with diabetes; HYPOGLYCEMIC agents; DRUG efficacy; MEDICATION safety; CD26 antigen; METFORMIN; RANDOMIZED controlled trials; DISEASES
- Publication
Diabetes, Obesity & Metabolism, 2015, Vol 17, Issue 3, p309
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1111/dom.12424